Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 784

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 784
---
,751 
 (10,202,353 
  14,252,518 
   4,050,165 | ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) |
|:-------------------------------------------------------------------------|:----|:------------------|------------:|:--|:----|:--------------|------------:|:--|
| Shares issued and reserved for asset acquisition                         |     | $                 |           — |   |     | $             |  15,000,000 |   |
| Right-of-useasset recognized in exchange for operating lease obligations |     |                   |     318,722 |   |     |               |           — |   |
| Debt issuance costs not yet paid                                         |     |                   |       5,135 |   |     |               |           — |   |
| Deferred offering costs not yet paid                                     |     |                   |     385,820 |   |     |               |           — |   |
| Derivative liability associated with make-whole premium                  |     |                   |   2,402,228 |   |     |               |           — |   |
| Fair value of warrants associated with convertible notes payable         |     |                   |   6,520,056 |   |     |               |           — |   |
| Deemed dividend on warrant modifications                                 |     |                   |     965,177 |   |     |               |           — |   |
| Issuance of common stock for placement agent fees                        |     |                   |     443,560 |   |     |               |           — |   |

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement. F-6 7

TUHURA BIOSCIENSES, INC AND SUBSIDIARY Notes to the condensed consolidated financial statements For the nine months ended September 30, 2024, and 2023 (Unaudited) Note 1—Description of business TuHURA Biosciences, Inc., a Delaware corporation (the “Company”), is a clinical stage immuno-oncology company developing novel personalized cancer vaccine product candidates designed to overcome primary resistance to immunotherapies like checkpoint inhibitors. The Company has entered into a Special Protocol Assessment agreement with the FDA for a single Phase 3 randomized placebo and injection-controlled trial for IFx-2.0,the Company’s lead personalized cancer vaccine product candidate, as adjunctive therapy to pembrolizumab (Key